Abstract: The present invention provides compounds of the formula: wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.

Abstract: Provided herein are compositions and methods of providing an effective amount of an N-acetylcysteine amide (NACA) or diNACA sufficient to increase the concentration of NACA or diNACA in the affected tissue to biochemically reduce oxidative stress-related damage to tissue; utilizing NACA or diNACA that comprises at least one of impurities B1 or B2, which are indicative of NACA or diNACA manufactured by a process comprising: contacting cystine with methanol and a chlorinating reagent to form an organic solution containing cystine dimethylester dihydrochloride and optionally isolating and drying the cystine dimethylester dihydrochloride; combining the dried or undried cystine dimethylester dihydrochloride with triethylamine, acetic anhydride, and acetonitrile to form di-N-acetylcystine dimethylester; mixing the di-N-acetylcystine dimethylester with ammonium hydroxide to form di-N-acetylcystine amide (diNACA or NPI-002); and reducing the di-N-acetylcystine amide to N-acetylcysteine, NACA or NPI-001 with a reducin

Abstract: A headgear system and/or an interface assembly incorporating a headgear system that, in some configurations, is configured to transform from elasticated or “stretchy” behavior to “inelastic” behavior at least in response to normal or expected forces encountered during the intended therapy. In some configurations, upon fitment to the head of a user, the system automatically adjusts toward or to an appropriate size. A headgear portion or assembly for use in combination with a breathing apparatus in some configurations is at least substantially inelastic and is three dimensional in shape. The headgear portion or assembly can comprise a plastic core and a textile casing. The headgear, or part thereof, may also have integrally moulded labels, connectors, adjustment mechanisms and/or grips.

Abstract: Provided herein are compositions and methods of providing an effective amount of an N-acetylcysteine amide (NACA) or diNACA sufficient to increase the concentration of NACA or diNACA in the affected tissue to biochemically reduce oxidative stress-related damage to tissue; utilizing NACA or diNACA that comprises at least one of impurities B1 or B2, which are indicative of NACA or diNACA manufactured by a process comprising: contacting cystine with methanol and a chlorinating reagent to form an organic solution containing cystine dimethylester dihydrochloride and optionally isolating and drying the cystine dimethylester dihydrochloride; combining the dried or undried cystine dimethylester dihydrochloride with triethylamine, acetic anhydride, and acetonitrile to form di-N-acetylcystine dimethylester; mixing the di-N-acetylcystine dimethylester with ammonium hydroxide to form di-N-acetylcystine amide (diNACA or NPI-002); and reducing the di-N-acetylcystine amide to N-acetylcysteine, NACA or NPI-001 with a reducin

Abstract: The present invention provides compounds of the formula: wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.

Abstract: An electronic substrate may be fabricated by forming a base substrate and forming an inductor extending through the base substrate, wherein the inductor includes a magnetic material layer and a barrier layer, such that the barrier layer prevents the magnetic material layer from leaching into plating solutions during the fabrication of the electronic substrate. In one embodiment, the barrier material may comprise titanium. In another embodiment, the barrier layer may comprise a polymeric material. In still another embodiment, the barrier layer may comprise a nitride material layer. The inductor may further include a plating seed layer on the barrier layer and a conductive fill material abutting the plating seed layer.

Abstract: A headgear system and/or an interface assembly incorporating a headgear system that, in some configurations, is configured to transform from elasticated or “stretchy” behavior to “inelastic” behavior at least in response to normal or expected forces encountered during the intended therapy. In some configurations, upon fitment to the head of a user, the system automatically adjusts toward or to an appropriate size. A headgear portion or assembly for use in combination with a breathing apparatus in some configurations is at least substantially inelastic and is three dimensional in shape. The headgear portion or assembly can comprise a plastic core and a textile casing. The headgear, or part thereof, may also have integrally moulded labels, connectors, adjustment mechanisms and/or grips.

Abstract: A respiratory mask system includes a mask interface and a headgear assembly. The headgear assembly is adjustable and comprised of an elastic portion, a non-elastic portion and a restriction mechanism configured to provide a force resisting movement of the non-elastic portion when the elastic portion is extended. There is a support beam coupled to the non-elastic portion and extending along a portion of the headgear that is curved along its longitudinal extent. In this way particular seal modules can be comfortably fitted to a user and any blow off force is mitigated. A particular example of the respiratory mask system includes provision for removable attachment between the seal and a mask frame, the mask frame and a yoke of the headgear; and between a conduit and the mask frame.

Abstract: Disclosed is a headgear for a patient interface, where the headgear includes a first and second lapped panels. The lapped panels define a lapped region in which the first and second panels respectively overlap and underlap each other. The lapped panels also define a non-lapped region in which the first panel is not lapped. At the lapped region, adjacent surfaces of the respective lapped panels are fused together.

Abstract: A headgear for a respiratory mask has first and second straps configured to be connected to each other by first and second buckles. The straps are configured to overlap in a region that contacts the rear of a user's head. The overlapping regions of the first and second straps can be positioned in a bifurcated configuration to improve stability on a user's head. The first and second buckles can feature a glider end through which one of the first and second straps can slide and a strap attachment end to which the other strap is permanently connected. In some embodiments, the first and second buckles have two components that are pivotally connected to allow adjustment of the headgear size whilst in a bifurcated configuration.

Abstract: A display device may include a flexible display surface element having a display surface, and an adjustment unit which includes a clamping element in form of a rod and arranged such that the rod moves in a first adjustment direction, a restoring element arranged on the clamping element, and a deflection element in form of a rod. A first side edge of the display surface element is arranged on a length of the clamping element. A second side edge of the display surface element opposite the first side edge is connected to the clamping element via the restoring element. A surface of the display surface element is bent and has a bending region. A length of the deflection element extends in same direction as the clamping element, the deflection element extends within the bending region of the bent display surface element and is arranged such that the deflection element moves in a second adjustment direction to change a distance between the deflection element and the clamping element.

Abstract: A respiratory interface assembly includes a patient interface and a headgear arrangement. A seal or cushion of the interface assembly can include thickened portions positioned and arranged to improve sealing and/or user comfort. The headgear arrangement can be connectable to the nasal mask by a connection arrangement configured to provide stability to the nasal mask such that a forehead support is not required. The connection arrangement can inhibit or prevent improper connections. The headgear arrangement can have one or more resilient straps having a composite construction of an outer fabric and a plastic core. The outer fabric can be knitted. A rear portion of the headgear arrangement can include a knitted panel or a spacer fabric panel.

Abstract: A headgear assembly can include a pair of opposing, semi-rigid side arms. Each side arm can be pivotally coupled to an interface at a single location. Each side arm can extend from the single location across the user's cheeks and above the user's ears in use. The headgear assembly can include a top strap coupled to the pair of opposing, semi-rigid side arms, the top strap configured to extend around the top of a user's head. The headgear assembly can include a rear strap coupled to the pair of opposing, semi-rigid side arms, the rear strap configured to extend around the rear of a user's head. The headgear assembly can include a chin strap coupled to the pair of opposing, semi-rigid side arms, the chin strap configured to extend around the user's chin.

Abstract: An electronic substrate may be fabricated by forming a base substrate and forming an inductor extending through the base substrate, wherein the inductor includes a magnetic material layer and a barrier layer, such that the barrier layer prevents the magnetic material layer from leaching into plating solutions during the fabrication of the electronic substrate. In one embodiment, the barrier material may comprise titanium. In another embodiment, the barrier layer may comprise a polymeric material. In still another embodiment, the barrier layer may comprise a nitride material layer. The inductor may further include a plating seed layer on the barrier layer and a conductive fill material abutting the plating seed layer.

Abstract: One embodiment provides a method, including: monitoring, using an accelerometer integrated with an information handling device, gravitational acceleration experienced by the information handling device; identifying, based on the monitoring, a change in the gravitational acceleration from a first gravitational acceleration metric to a second gravitational acceleration metric; and adjusting, responsive to the identifying, a time-keeping standard referenced by the information handling device based on the second gravitational acceleration metric. Other aspects are described and claimed.

Abstract: A system may include a processor that may receive account information having a plurality of transactions associated with a bank account. The processor may then determine an expected burn rate of funds based on the account information, determine an expected savings balance at a first time based on the account information and the expected burn rate, generate an event in response to the expected savings balance being below a threshold, and send an alert including the event to a computing device associated with the user. The alert may indicate a status of the expected savings balance via an electronic display of the computing device.

Abstract: The present invention includes pharmaceutical composition comprising deuterated NACA-d3, deuterated di-NACA-d6, combinations thereof, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using NACA-d3, di-NACA-d6, or combinations thereof, to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuvenation, antimicrobial infection, Friedreich's ataxia.

Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.